Attovia Therapeutics, Inc.

NASDAQ:ATTO

Biotechnology

Healthcare
$15.53 -1.20%

-$0.18 today

Market cap
$709.92M
Beta
0.00
P/E (TTM)
-15.9
EPS (TTM)
-$0.86
52W Low $14.23High $28.00

Volume 0.34M

Average 0.45M

ATTO Common Stock Repurchased

Cash spent buying back the company's own shares.

Attovia Therapeutics, Inc.NASDAQ: ATTO

Common Stock Repurchased · Q2 FY2026 · quarter ended Jun 2026

Common stock repurchased of $0 in Q2 FY2026

Q2 FY2026 common stock repurchased was $0.

Context

  • Common stock repurchased amounted to 0.0% of revenue in FY2025.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Common Stock Repurchased past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Common Stock Repurchased history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Common Stock Repurchased vs competitors

How ATTO compares with its peers on the latest reported figures

  • ATTO's FY2025 common stock repurchased of $0 is the 4th largest of the 10 companies compared; the peer median is $0.
  • Common stock repurchased amounts to 0.0% of revenue for ATTO, versus a peer median of 0.1%.
ATTO Competitors Peer median
Common Stock Repurchased for ATTO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANABAnaptysBio, Inc.LTM Mar 2026$64.2M +1215.6%—27.6%
ALMSAlumis Inc. Common StockLTM Jun 2026$17K +200.0%—0.2%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$9K -96.9%—0.1%
ATTOAttovia Therapeutics, Inc.FY2025$0 ——0.0%
ORKAOruka Therapeutics, Inc.LTM Sep 2026$0 ———
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$0 ———
EVMNEvommune, Inc.LTM Mar 2026$0 ——0.0%
QTTBQ32 Bio Inc.LTM Mar 2026$0 ——0.0%
ZURAZura Bio LimitedLTM Mar 2026$0 ———
CNTBConnect Biopharma Holdings LimitedFY2025$0 ——0.0%
AGMBAgomAb Therapeutics N.V. American Depositary Shares—— ———
Peer median (excluding ATTO) $0+200.0%—0.1%

Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Attovia Therapeutics, Inc.

NASDAQ:ATTO

Intrinsic Alpha fair value

Locked

Current Price

$15.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.